Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery
Tomofumi Tsuboi, Tamito Sasaki, Masahiro Serikawa, Yasutaka Ishii, Teruo Mouri, Akinori Shimizu, Keisuke Kurihara, Yumiko Tatsukawa, Eisuke Miyaki, Ryota Kawamura, Ken Tsushima, Yoshiaki Murakami, Kenichiro Uemura, Kazuaki Chayama, Tomofumi Tsuboi, Tamito Sasaki, Masahiro Serikawa, Yasutaka Ishii, Teruo Mouri, Akinori Shimizu, Keisuke Kurihara, Yumiko Tatsukawa, Eisuke Miyaki, Ryota Kawamura, Ken Tsushima, Yoshiaki Murakami, Kenichiro Uemura, Kazuaki Chayama
Abstract
Objective. To elucidate the optimum preoperative biliary drainage method for patients with pancreatic cancer treated with neoadjuvant chemotherapy (NAC). Material and Methods. From January 2010 through December 2014, 20 patients with borderline resectable pancreatic cancer underwent preoperative biliary drainage and NAC with a plastic or metallic stent and received NAC at Hiroshima University Hospital. We retrospectively analyzed delayed NAC and complication rates due to biliary drainage, effect of stent type on perioperative factors, and hospitalization costs from diagnosis to surgery. Results. There were 11 cases of preoperative biliary drainage with plastic stents and nine metallic stents. The median age was 64.5 years; delayed NAC occurred in 9 cases with plastic stent and 1 case with metallic stent (p = 0.01). The complication rates due to biliary drainage were 0% (0/9) with metallic stents and 72.7% (8/11) with plastic stents (p = 0.01). Cumulative rates of complications determined with the Kaplan-Meier method on day 90 were 60% with plastic stents and 0% with metallic stents (log-rank test, p = 0.012). There were no significant differences between group in perioperative factors or hospitalization costs from diagnosis to surgery. Conclusions. Metallic stent implantation may be effective for preoperative biliary drainage for pancreatic cancer treated with NAC.
Figures
References
- Egawa S., Toma H., Ohigashi H., et al. Japan pancreatic cancer registry; 30th year anniversary: Japan pancreas society. Pancreas. 2012;41(7):985–992. doi: 10.1097/MPA.0b013e318258055c.
- Neoptolemos J. P., Dunn J. A., Stocken D. D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. The Lancet. 2001;358(9293):1576–1585. doi: 10.1016/s0140-6736(01)06651-x.
- Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. The Journal of the American Medical Association. 2007;297(3):267–277. doi: 10.1001/jama.297.3.267.
- Ueno H., Kosuge T., Matsuyama Y., et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. British Journal of Cancer. 2009;101(6):908–915. doi: 10.1038/sj.bjc.6605256.
- Neoptolemos J. P., Stocken D. D., Bassi C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. The Journal of the American Medical Association. 2010;304(10):1073–1081. doi: 10.1001/jama.2010.1275.
- Davids P. H. P., Groen A. K., Rauws E. A. J., Tytgat G. N. J., Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. The Lancet. 1992;340(8834-8835):1488–1492. doi: 10.1016/0140-6736(92)92752-2.
- van der Gaag N. A., Rauws E. A. J., Van Eijck C. H. J., et al. Preoperative biliary drainage for cancer of the head of the pancreas. The New England Journal of Medicine. 2010;362(2):129–137. doi: 10.1056/nejmoa0903230.
- Moss A. C., Morris E., Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database of Systematic Reviews. 2006;(1)CD004200
- Arguedas M. R., Heudebert G. H., Stinnett A. A., Wilcox C. M. Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. The American Journal of Gastroenterology. 2002;97(4):898–904. doi: 10.1016/s0002-9270(02)03962-x.
- Kaassis M., Boyer J., Dumas R., et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointestinal Endoscopy. 2003;57(2):178–182. doi: 10.1067/mge.2003.66.
- Siddiqui A. A., Mehendiratta V., Loren D., et al. Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in 241 patients. Digestive Diseases and Sciences. 2013;58(6):1744–1750. doi: 10.1007/s10620-012-2482-z.
- Kato H., Usui M., Isaji S., et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Sciences. 2013;20(6):601–610. doi: 10.1007/s00534-013-0595-1.
- Kim E. J., Ben-Josef E., Herman J. M., et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119(15):2692–2700. doi: 10.1002/cncr.28117.
- Kang C. M., Chung Y. E., Park J. Y., et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. Journal of Gastrointestinal Surgery. 2012;16(3):509–517. doi: 10.1007/s11605-011-1784-3.
- Katz M. H. G., Fleming J. B., Bhosale P., et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–5756. doi: 10.1002/cncr.27636.
- Lee J.-L., Kim S. C., Kim J.-H., et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152(5):851–862. doi: 10.1016/j.surg.2012.03.010.
- Patel M., Hoffe S., Malafa M., et al. Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. Journal of Surgical Oncology. 2011;104(2):155–161. doi: 10.1002/jso.21954.
- Stokes J. B., Nolan N. J., Stelow E. B., et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Annals of Surgical Oncology. 2011;18(3):619–627. doi: 10.1245/s10434-010-1456-7.
- Varadhachary G. R., Tamm E. P., Abbruzzese J. L., et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Annals of Surgical Oncology. 2006;13(8):1035–1046. doi: 10.1245/aso.2006.08.011.
- Wolff R. A., Varadhachary G. R., Evans D. B. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Annals of Surgical Oncology. 2008;15(10):2773–2786. doi: 10.1245/s10434-008-0002-3.
- Boulay B. R., Gardner T. B., Gordon S. R. Occlusion rate and complications of plastic biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for pancreatic cancer with malignant biliary obstruction. Journal of Clinical Gastroenterology. 2010;44(6):452–455. doi: 10.1097/mcg.0b013e3181d2ef06.
- Mullen J. T., Lee J. H., Gomez H. F., et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. Journal of Gastrointestinal Surgery. 2005;9(8):1094–1105. doi: 10.1016/j.gassur.2005.08.006.
- Wasan S. M., Ross W. A., Staerkel G. A., Lee J. H. Use of expandable metallic biliary stents in resectable pancreatic cancer. American Journal of Gastroenterology. 2005;100(9):2056–2061. doi: 10.1111/j.1572-0241.2005.42031.x.
- Aadam A. A., Evans D. B., Khan A., Oh Y., Dua K. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointestinal Endoscopy. 2012;76(1):67–75. doi: 10.1016/j.gie.2012.02.041.
- Decker C., Christein J. D., Phadnis M. A., Mel Wilcox C., Varadarajulu S. Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer. Surgical Endoscopy. 2011;25(7):2364–2367. doi: 10.1007/s00464-010-1552-6.
- McClaine R. J., Lowy A. M., Sussman J. J., Schmulewitz N., Grisell D. L., Ahmad S. A. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB. 2010;12(1):73–79. doi: 10.1111/j.1477-2574.2009.00136.x.
- Kubota K., Sato T., Watanabe S., Hosono K., Kobayashi N., Mori R. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic cancer. Digestive Endoscopy. 2014;26:77–86.
- Kato K., Kondo S., Hirano S., et al. Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. Journal of Hepato-Biliary-Pancreatic Sciences. 2011;18(5):712–716. doi: 10.1007/s00534-011-0391-8.
- Siddiqui A., Mehendiratta V., Loren D., et al. Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in 241 patients. Digestive Diseases and Sciences. 2013;58(6):1744–1750. doi: 10.1007/s10620-012-2482-z.
Source: PubMed